CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade ALX Oncology Holdings Inc. - ALXO CFD

    15.88
    1.78%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    Trading сonditions
    Spread 0.11
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026179 %
    Charges from full value of position ($-4.97)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026179%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003957 %
    Charges from full value of position ($0.75)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003957%
    Overnight fee time 21:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    ALX Oncology Holdings Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 15.69
    Open* 15.49
    1-Year Change* 235.28%
    Day's Range* 15.49 - 16.04
    52 wk Range 3.94-15.93
    Average Volume (10 days) 301.97K
    Average Volume (3 months) 9.54M
    Market Cap 635.69M
    P/E Ratio -100.00K
    Shares Outstanding 49.82M
    Revenue N/A
    EPS -3.57
    Dividend (Yield %) N/A
    Beta 1.67
    Next Earnings Date Mar 7, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Apr 18, 2024 15.69 -0.05 -0.32% 15.74 16.03 15.07
    Apr 17, 2024 16.05 1.56 10.77% 14.49 17.00 14.49
    Apr 16, 2024 14.42 2.07 16.76% 12.35 14.54 12.35
    Apr 15, 2024 12.82 0.14 1.10% 12.68 13.02 12.11
    Apr 12, 2024 13.02 -0.02 -0.15% 13.04 13.48 12.48
    Apr 11, 2024 13.35 1.35 11.25% 12.00 13.67 11.78
    Apr 10, 2024 12.01 0.22 1.87% 11.79 12.11 11.64
    Apr 9, 2024 12.32 0.13 1.07% 12.19 12.52 11.77
    Apr 8, 2024 12.14 0.15 1.25% 11.99 12.68 11.99
    Apr 5, 2024 12.24 1.18 10.67% 11.06 12.25 10.68
    Apr 4, 2024 11.23 0.44 4.08% 10.79 11.27 10.79
    Apr 3, 2024 10.79 0.06 0.56% 10.73 10.91 10.48
    Apr 2, 2024 10.70 0.21 2.00% 10.49 10.91 10.49
    Apr 1, 2024 11.01 0.10 0.92% 10.91 11.30 10.60
    Mar 28, 2024 11.15 -0.24 -2.11% 11.39 11.44 10.55
    Mar 27, 2024 11.39 0.21 1.88% 11.18 11.59 10.94
    Mar 26, 2024 11.17 -0.62 -5.26% 11.79 11.82 11.16
    Mar 25, 2024 11.70 0.19 1.65% 11.51 12.14 11.47
    Mar 22, 2024 11.73 -0.42 -3.46% 12.15 12.32 11.46
    Mar 21, 2024 12.48 0.61 5.14% 11.87 12.65 11.84

    ALX Oncology Holdings Inc. Events

    Time (UTC) Country Event
    Thursday, May 9, 2024

    Time (UTC)

    10:59

    Country

    US

    Event

    Q1 2024 ALX Oncology Holdings Inc Earnings Release
    Q1 2024 ALX Oncology Holdings Inc Earnings Release

    Forecast

    -

    Previous

    -
    Friday, June 14, 2024

    Time (UTC)

    20:00

    Country

    US

    Event

    ALX Oncology Holdings Inc Annual Shareholders Meeting
    ALX Oncology Holdings Inc Annual Shareholders Meeting

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 0 0 1.182 4.796 2.067
    Revenue 0 0 1.182 4.796 2.067
    Cost of Revenue, Total 0 1.075 4.36 1.88
    Gross Profit 0 0.107 0.436 0.187
    Total Operating Expense 127.436 83.555 45.466 23.979 15.751
    Selling/General/Admin. Expenses, Total 29.036 23.385 14.809 3.313 2.601
    Research & Development 98.4 60.17 28.961 16.306 11.27
    Operating Income -127.436 -83.555 -44.284 -19.183 -13.684
    Interest Income (Expense), Net Non-Operating 4.278 -0.013 -0.811 -0.021 0
    Other, Net -0.26 0.084 -0.404 -0.005 -0.002
    Net Income Before Taxes -123.418 -83.484 -45.499 -19.209 -13.686
    Net Income After Taxes -123.482 -83.463 -45.74 -19.243 -13.731
    Net Income Before Extra. Items -123.482 -83.463 -45.74 -19.243 -13.731
    Net Income -123.482 -83.463 -45.74 -19.243 -13.731
    Total Adjustments to Net Income 0 0 -5.202 -4.028 -3.671
    Income Available to Common Excl. Extra. Items -123.482 -83.463 -50.942 -23.271 -17.402
    Income Available to Common Incl. Extra. Items -123.482 -83.463 -50.942 -23.271 -17.402
    Diluted Net Income -123.482 -83.463 -50.942 -23.271 -17.402
    Diluted Weighted Average Shares 40.6996 40.308 18.4853 34.7116 34.7116
    Diluted EPS Excluding Extraordinary Items -3.03398 -2.07063 -2.7558 -0.67041 -0.50133
    Dividends per Share - Common Stock Primary Issue 0 0
    Diluted Normalized EPS -3.03398 -2.07063 -2.73397 -0.67041 -0.50133
    Unusual Expense (Income) 0 0 0.621
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 0 0 0 0 0
    Revenue
    Total Operating Expense 36.777 32.203 32.219 36.681 33.789
    Selling/General/Admin. Expenses, Total 7.295 7.44 7.022 7.299 7.041
    Research & Development 29.482 24.763 25.197 29.382 26.748
    Operating Income -36.777 -32.203 -32.219 -36.681 -33.789
    Interest Income (Expense), Net Non-Operating 2.294 1.924 1.807 1.37 0.876
    Other, Net 0.324 0.095 -0.233 -0.009 -0.007
    Net Income Before Taxes -34.159 -30.184 -30.645 -35.32 -32.92
    Net Income After Taxes -34.159 -30.184 -30.709 -35.32 -32.92
    Net Income Before Extra. Items -34.159 -30.184 -30.709 -35.32 -32.92
    Net Income -34.159 -30.184 -30.709 -35.32 -32.92
    Total Adjustments to Net Income
    Income Available to Common Excl. Extra. Items -34.159 -30.184 -30.709 -35.32 -32.92
    Income Available to Common Incl. Extra. Items -34.159 -30.184 -30.709 -35.32 -32.92
    Diluted Net Income -34.159 -30.184 -30.709 -35.32 -32.92
    Diluted Weighted Average Shares 40.8755 40.8625 40.7459 40.747 40.6878
    Diluted EPS Excluding Extraordinary Items -0.83568 -0.73867 -0.75367 -0.86681 -0.80909
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.83568 -0.73867 -0.75367 -0.86681 -0.80909
    Cost of Revenue, Total
    Gross Profit
    Unusual Expense (Income) 0
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 270.969 367.019 435.992 9.809 10.208
    Cash and Short Term Investments 266.207 363.667 434.219 9.017 8.262
    Cash 434.219 9.017 8.262
    Total Receivables, Net 0 0.536 0.932
    Accounts Receivable - Trade, Net 0 0.536 0.932
    Prepaid Expenses 4.762 3.352 1.773 0.256 1.014
    Total Assets 306.489 380.183 436.054 10.676 11.164
    Property/Plant/Equipment, Total - Net 9.789 3.397 0.052 0.86 0.956
    Property/Plant/Equipment, Total - Gross 10.192 3.46 0.077 2.309 1.976
    Accumulated Depreciation, Total -0.403 -0.063 -0.025 -1.449 -1.02
    Other Long Term Assets, Total 9.032 9.767 0.01 0.007 0
    Total Current Liabilities 28.325 15.295 6.204 4.984 1.873
    Accounts Payable 8.073 3.764 0.004 3.748 0.697
    Accrued Expenses 19.792 11.102 6.049 1.046 0.905
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 0.174 0.151 0.19 0.271
    Total Liabilities 43.025 17.134 6.209 10.952 2.009
    Total Long Term Debt 9.389 0.28 0 5.421 0
    Long Term Debt 9.389 5.421 0
    Other Liabilities, Total 5.311 1.559 0.005 0.547 0.136
    Total Equity 263.464 363.049 429.845 -0.276 9.155
    Preferred Stock - Non Redeemable, Net 70.363 60.933
    Common Stock 0.041 0.041 0.04 0.021 0.021
    Additional Paid-In Capital 589.735 564.993 548.327 2.122 1.74
    Retained Earnings (Accumulated Deficit) -325.467 -201.985 -118.522 -72.782 -53.539
    Total Liabilities & Shareholders’ Equity 306.489 380.183 436.054 10.676 11.164
    Total Common Shares Outstanding 40.8614 40.5871 39.8445 34.7116 34.7116
    Redeemable Preferred Stock 0
    Cash & Equivalents 48.822 363.667
    Current Port. of LT Debt/Capital Leases 0.286 0.429
    Capital Lease Obligations 0 0.28
    Short Term Investments 217.385
    Long Term Investments 16.699
    Other Equity, Total -0.845
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 199.071 219.561 232.536 270.969 290.808
    Cash and Short Term Investments 190.009 212.836 227.944 266.207 284.909
    Cash & Equivalents 19.584 38.039 63.194 48.822 49.054
    Prepaid Expenses 8.462 6.225 3.792 4.762 5.899
    Total Assets 220.107 245.932 278.138 306.489 317.689
    Property/Plant/Equipment, Total - Net 9.808 9.066 9.551 9.789 8.639
    Property/Plant/Equipment, Total - Gross 10.84 9.889 10.167 10.192 8.939
    Accumulated Depreciation, Total -1.032 -0.823 -0.616 -0.403 -0.3
    Other Long Term Assets, Total 4.793 5.658 7.831 9.032 10.025
    Total Current Liabilities 35.142 17.572 21.891 28.325 25.243
    Accounts Payable 13.001 4.115 9.826 8.073 5.88
    Accrued Expenses 21.151 12.409 11.628 19.792 18.97
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 0.179 0.286 0.393
    Other Current Liabilities, Total 0.99 1.048 0.258 0.174
    Total Liabilities 51.355 33.24 37.75 43.025 30.726
    Total Long Term Debt 9.575 9.512 9.45 9.389 0
    Capital Lease Obligations 0 0 0
    Other Liabilities, Total 6.638 6.156 6.409 5.311 5.483
    Total Equity 168.752 212.692 240.388 263.464 286.963
    Redeemable Preferred Stock
    Common Stock 0.041 0.041 0.041 0.041 0.041
    Additional Paid-In Capital 609.737 602.773 596.086 589.735 583.184
    Retained Earnings (Accumulated Deficit) -440.8 -389.81 -355.651 -325.467 -294.758
    Total Liabilities & Shareholders’ Equity 220.107 245.932 278.138 306.489 317.689
    Total Common Shares Outstanding 41.1518 40.9922 40.863 40.8614 40.7483
    Short Term Investments 170.425 174.797 164.75 217.385 235.855
    Long Term Investments 6.435 11.647 28.22 16.699 8.217
    Other Equity, Total -0.226 -0.312 -0.088 -0.845 -1.504
    Long Term Debt 9.575 9.512 9.45 9.389
    Total Receivables, Net 0.6 0.5 0.8
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -123.482 -83.463 -45.74 -19.243 -13.731
    Cash From Operating Activities -89.223 -68.101 -38.289 -14.249 -13.19
    Cash From Operating Activities 0.342 0.051 0.202 0.429 0.431
    Non-Cash Items 24.067 19.338 7.002 0.308 0.269
    Changes in Working Capital 9.85 -4.027 0.247 4.257 -0.159
    Cash From Investing Activities -235.416 -4.923 0.61 -0.353 -0.653
    Capital Expenditures -1.427 -4.923 -0.031 -0.353 -0.653
    Cash From Financing Activities 9.86 2.472 462.881 15.357 0.001
    Issuance (Retirement) of Stock, Net 0.903 2.753 473.235 9.44 0.001
    Issuance (Retirement) of Debt, Net 9.612 -0.281 0 5.917 0
    Net Change in Cash -314.779 -70.552 425.202 0.755 -13.842
    Cash Taxes Paid 0 0.274 0.047
    Cash Interest Paid 0.103 0.011 0.427
    Other Investing Cash Flow Items, Total -233.989 0.641
    Financing Cash Flow Items -0.655 -10.354
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -30.184 -123.482 -92.773 -57.453 -24.533
    Cash From Operating Activities -27.816 -89.223 -68.555 -37.672 -20.674
    Cash From Operating Activities 0.213 0.342 0.237 0.142 0.058
    Non-Cash Items 5.603 24.067 18.104 11.954 5.926
    Cash Interest Paid 0 0.103 0 0 0
    Changes in Working Capital -3.448 9.85 5.877 7.685 -2.125
    Cash From Investing Activities 42.295 -235.416 -246.358 -260.053 -183.921
    Capital Expenditures -0.69 -1.427 -1.038 -0.846 -0.589
    Cash From Financing Activities -0.107 9.86 0.366 0.502 0.08
    Issuance (Retirement) of Stock, Net 0 0.903 0.647 0.642 0.185
    Net Change in Cash 14.372 -314.779 -314.547 -297.223 -204.515
    Cash Taxes Paid 0 0 0 0 0
    Financing Cash Flow Items -0.655
    Issuance (Retirement) of Debt, Net -0.107 9.612 -0.281 -0.14 -0.105
    Other Investing Cash Flow Items, Total 42.985 -233.989 -245.32 -259.207 -183.332

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    ALX Oncology Holdings Inc. Company profile

    About ALX Oncology Holdings Inc

    ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company. The Company is focused on enabling patients to fight cancer by developing therapies that block the cluster of differentiation 47 (CD47) checkpoint pathway and bridge the innate and adaptive immune system. The Company is developing a checkpoint inhibitor designed to have an affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches. Its lead product candidate, ALX148, is a CD47 blocking therapeutic. ALX148 is a fusion protein that combines a CD47 binding domain with its inactivated fragment crystallizable (Fc) domain. The CD47 binding domain of ALX148 is an affinity enhanced extracellular domain of signal regulatory protein alpha (SIRPa), a protein that is the natural receptor to CD47 found on myeloid cells. Its programs are focused on targeting CD47 across various oncology indications.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, ALX Oncology Holdings Inc revenues decreased from $1.2M to $0K. Net loss applicable to common stockholders increased 64% to $83.5M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Reserach and developement increase of 76% to $46.5M (expense).

    Industry: Bio Therapeutic Drugs

    323 Allerton Avenue
    SOUTH SAN FRANCISCO
    CALIFORNIA 94080
    US

    Income Statement

    • Annual
    • Quarterly

    News

    Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

    Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

    07:56, 17 April 2024

    US Earnings Season : JP Morgan, Citigroup, Wells Fargo

    The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

    16:03, 11 April 2024

    Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

    The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

    09:22, 11 April 2024

    US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

    US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

    15:11, 9 April 2024

    How escalating geopolitical tensions are impacting oil markets

    The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

    13:34, 4 April 2024

    A way forward: a roundup of recent central bank decisions

    Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

    12:47, 22 March 2024

    Bank of Japan Preview: will the BOJ end negative interest rates?

    The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

    08:44, 18 March 2024

    People also watch

    XRP/USD

    0.51 Price
    -0.430% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 21:00 (UTC)
    Spread 0.01168

    US100

    17,289.40 Price
    -0.290% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 21:00 (UTC)
    Spread 1.8

    ETH/USD

    3,096.68 Price
    +1.100% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 6.00

    Gold

    2,386.15 Price
    +0.240% 1D Chg, %
    Long position overnight fee -0.0190%
    Short position overnight fee 0.0108%
    Overnight fee time 21:00 (UTC)
    Spread 0.40

    Still looking for a broker you can trust?

    Join the 610,000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading